Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
271.6 EUR | -2.62% | -18.90% | -18.49% |
Apr. 19 | SARTORIUS VORZUEGE : Deutsche Bank reaffirms its Neutral rating | ZD |
Apr. 18 | German Shares Close Green as Bundesbank Sees Q1 Economic Growth | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 68.33 and 46.97 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.49% | 17.98B | A | ||
-46.92% | 2.56B | C+ | ||
+7.27% | 1.66B | - | - | |
-15.17% | 1.45B | - | ||
+18.55% | 1.2B | B+ | ||
-15.69% | 978M | - | ||
-24.43% | 875M | - | C- | |
-9.20% | 698M | - | ||
-17.12% | 687M | B+ | ||
+5.90% | 480M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SRT3 Stock
- Ratings Sartorius AG